Totient, an AI-driven drug discovery platform, raised $10 million in a seed funding round.
Investors include Mission BioCapital, Sands Capital, Viva Biotech, Kaitai Capital, Tau Ventures, and Jonathan Milner.
With seed funds, Totient intends to advance a subset of their proprietary antibodies into the clinic while pursuing a broad and flexible partnering strategy for other candidates in parallel.
Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. Totient uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble the most potent antibody candidates.
“TLSs are a largely untapped source of naturally evolved, fully-human antibodies. Totient’s technology enables successful assembly of antibodies from TLSs across thousands of samples,” said Daniele Biasci, Totient VP of Immunology, on whose hypothesis the program was built.
According to Jonathan Milner, co-founder and Deputy Chairman of Abcam, “Totient has demonstrated an ability to correctly assemble antibodies from bulk patient RNA sequencing data, without the need for specialized single-cell or antibody sequencing. The approach enables Totient to express and screen antibodies from large and noisy archival datasets, without prior target knowledge.”
Image by Steve Buissinne from Pixabay